Mabion Valuation

Is MAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MAB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MAB?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MAB. This is calculated by dividing MAB's market cap by their current preferred multiple.
What is MAB's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	zł286.72m

MAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	3.7x
PEG Ratio	-0.07x

Price to Earnings Ratio vs Peers

How does MAB's PE Ratio compare to its peers?

The above table shows the PE ratio for MAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	43.3x
SVE Synthaverse	92.5x	n/a	zł335.2m
GEN Genomed Spólka Akcyjna	64.6x	n/a	zł38.1m
SPRO Spero Therapeutics	4.1x	20.3%	US$71.1m
2INV 2invest	12x	n/a	€60.4m
MAB Mabion	6.8x	-99.5%	zł286.7m

Price-To-Earnings vs Peers: MAB is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (43.3x).

Price to Earnings Ratio vs Industry

How does MAB's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: MAB is good value based on its Price-To-Earnings Ratio (6.8x) compared to the European Biotechs industry average (29.2x).

Price to Earnings Ratio vs Fair Ratio

What is MAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	6.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MAB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MAB forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	zł17.74	zł15.50 -12.6%	14.7%	zł18.50	zł13.00	n/a	3
Aug ’25	zł17.86	zł15.83 -11.3%	14.2%	zł18.50	zł13.00	n/a	3
Jul ’25	zł17.14	zł15.83 -7.6%	14.2%	zł18.50	zł13.00	n/a	3
Jun ’25	zł16.66	zł15.83 -5.0%	14.2%	zł18.50	zł13.00	n/a	3
May ’25	zł16.28	zł15.83 -2.7%	14.2%	zł18.50	zł13.00	n/a	3
Apr ’25	zł16.30	zł15.57 -4.5%	7.3%	zł16.70	zł14.00	n/a	3
Mar ’25	zł16.99	zł15.57 -8.4%	7.3%	zł16.70	zł14.00	n/a	3
Feb ’25	zł18.13	zł15.57 -14.1%	7.3%	zł16.70	zł14.00	n/a	3
Jan ’25	zł18.15	zł15.57 -14.2%	7.3%	zł16.70	zł14.00	n/a	3
Dec ’24	zł21.48	zł15.57 -27.5%	7.3%	zł16.70	zł14.00	n/a	3
Nov ’24	zł17.00	zł15.35 -9.7%	8.8%	zł16.70	zł14.00	n/a	2
Oct ’24	zł16.99	zł15.35 -9.7%	8.8%	zł16.70	zł14.00	n/a	2
Sep ’24	zł16.79	zł15.35 -8.6%	8.8%	zł16.70	zł14.00	zł18.54	2
Aug ’24	zł18.00	zł15.35 -14.7%	8.8%	zł16.70	zł14.00	zł17.86	2
Jul ’24	zł16.44	zł15.35 -6.6%	8.8%	zł16.70	zł14.00	zł17.14	2
Jun ’24	zł17.00	zł15.35 -9.7%	8.8%	zł16.70	zł14.00	zł16.66	2
May ’24	zł18.45	zł14.75 -20.1%	5.1%	zł15.50	zł14.00	zł16.28	2
Apr ’24	zł17.82	zł15.75 -11.6%	1.6%	zł16.00	zł15.50	zł16.30	2
Mar ’24	zł20.69	zł15.75 -23.9%	1.6%	zł16.00	zł15.50	zł16.99	2
Feb ’24	zł22.64	zł15.75 -30.4%	1.6%	zł16.00	zł15.50	zł18.13	2
Jan ’24	zł21.00	zł15.75 -25.0%	1.6%	zł16.00	zł15.50	zł18.15	2
Dec ’23	zł21.57	zł16.25 -24.7%	4.6%	zł17.00	zł15.50	zł21.48	2
Nov ’23	zł20.70	zł16.25 -21.5%	4.6%	zł17.00	zł15.50	zł17.00	2
Oct ’23	zł20.61	zł26.00 +26.2%	7.7%	zł28.00	zł24.00	zł16.99	2
Sep ’23	zł23.00	zł26.00 +13.0%	7.7%	zł28.00	zł24.00	zł16.79	2

Analyst Forecast: Target price is lower than the current share price.